RxDoctor Payments Data

Danyelle Loveless, MD

Family Medicine · Indianapolis, INNPI 1528089844

Payments from drug & device makers

$8,885in general payments, 2019–2025

Across 464 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$651
  • Lilly USA, LLC$584
  • Pfizer$504
  • Astellas Pharma US Inc$454
  • plus $3K from 48 others

What the payments were for

  • Food & beverage$8,873100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,885 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$50,356
Medicare patients
155
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$208,371
JardianceEmpagliflozin46$39,049
MounjaroTirzepatide23$25,603
JanuviaSitagliptin Phosphate28$22,184
EliquisApixaban19$21,216
XareltoRivaroxaban21$16,249
TradjentaLinagliptin14$13,546
TrulicityDulaglutide12$12,385
LinzessLinaclotide14$12,357
Breo ElliptaFluticasone/Vilanterol27$11,577
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$8,921
VascepaIcosapent Ethyl16$7,969
SymbicortBudesonide/Formoterol Fumarate14$6,746
Eletriptan HbrEletriptan Hydrobromide14$4,834
Risedronate Sodium25$3,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,883$208,371149 claims
Boehringer IngelheimJardiance, Tradjenta$385$52,59560 claims
Lilly USA, LLCMounjaro, Trulicity$584$37,98835 claims
MerckJanuvia$218$22,18428 claims
PfizerEliquis$504$21,21619 claims
Johnson & JohnsonXarelto$82$16,24921 claims
GSKBreo Ellipta, Shingrix$62$14,62641 claims
AbbVieLinzess, Synthroid$1,494$13,68741 claims
AstraZenecaSymbicort$651$6,74614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →